Trade & Investment

Haicang Biological and New Pharmaceutical Park

Updated: 2014-02-11
Share this news?...Click box   Bookmark and Share
   
Haicang Biological and New Pharmaceutical Park is a state-approved “Fujian-Taiwan (Xiamen) Biopharmaceutical Industrial Base” and “National Patent Industrialization (Xiamen) Pilot Base”. It includes a biopharmaceutical incubator, a biopharmaceutical pilot experiment and industrialization base and a biological and new pharmaceutical industrial core park.

As of the end of 2012, the Park had accommodated 93 biopharmaceutical enterprises of gene engineering, protein medicine, vaccine, in-vitro diagnostic reagent, medical instruments and health care products. In 2012, Haicang’s biological and new medicine outputs accounted for a quarter of the total outputs of Fujian Province.

Xiamen Biopharmaceutical Incubator has an incubation area of 8,000 square meters. It has a professional analytical and test center, an open biopharmaceutical professional lab and a pilot experiment workshop. It is also furnished with world-class instruments and equipments to provide comprehensive project incubation and all-around and professional technical services for biopharmaceutical enterprises. In 2008, a “post-doctoral scientific research workstation” was approved by the Ministry of Personnel to be set up in Xiamen Biopharmaceutical Incubator and included as a “National Torch Project” by the Ministry of Science and Technology.

Xiamen Biopharmaceutical Pilot Experiment and Industrialization Base is located 200 meters away from Xiamen Biopharmaceutical Incubator and, in conjunction with the latter, and provides all-around services such as achievements transformation and sharing platform, technical supports, investment and financing counseling and training. It is planned to have 4 biopharmaceutical GMP pilot experiment units, 1 technical service center and 1 industrialization unit.

Xiamen Biopharmaceutical Port covers a planned area of about 100,000 square kilometers, giving priority to the development of recombination gene medicine, vaccine, diagnostic reagent, blood products and other bio-pharmaceuticals; medical instruments and equipments directed at diagnose, treatment and intensive care, chemical drugs and Chinese traditional medicine; health care food and other biotechnology products. 
 
SOURCE:
www.xiameninvest.com
 
Editorial Message
This site contains materials from other clearly stated media sources for the purpose of discussion stimulation and content enrichment among our members only.
whatsonxiamen.com does not necessarily endorse their views or the accuracy of their content. For copyright infringement issues please contact editor@whatsonxiamen.com
Share this news?...Click box   Bookmark and Share
Comments Area ( Total Comments: 0 )